mRNA Synthesis Raw Material Market Size, Trends & Growth Report by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global mRNA Synthesis Raw Material Market Size Analysis

Global mRNA Synthesis Raw Material Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Capping Agents
  1. By Value
  2. CleanCap Reagents
    1. CleanCap Reagents By Value
  3. ARCA (Anti-Reverse Cap Analog)
    1. ARCA (Anti-Reverse Cap Analog) By Value
  4. Others
    1. Others By Value
3. Nucleotides
  1. By Value
  2. Modified Nucleic Acids
    1. Modified Nucleic Acids By Value
    2. N1-methylpseudouridine-triphosphate
      1. N1-methylpseudouridine-triphosphate By Value
    3. 5-Methylcytidine triphosphate (5mCTP)
      1. 5-Methylcytidine triphosphate (5mCTP) By Value
    4. Others
      1. Others By Value
4. Natural Nucleic Acids
  1. By Value
  2. Adenine
    1. Adenine By Value
  3. Guanine
    1. Guanine By Value
  4. Cytosine
    1. Cytosine By Value
  5. Uracil
    1. Uracil By Value
5. Plasmid DNA
  1. By Value
6. Enzymes
  1. By Value
  2. Polymerase
    1. Polymerase By Value
  3. RNase Inhibitor
    1. RNase Inhibitor By Value
  4. DNase
    1. DNase By Value
  5. Others
    1. Others By Value
By Application
1. Introduction
  1. Application By Value
2. Vaccine Production
  1. By Value
3. Therapeutics Production
  1. By Value
4. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Biopharmaceutical & Pharmaceutical Companies
  1. By Value
3. CROs & CMOs
  1. By Value
4. Academic & Research Institutes
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Capping Agents
  1. By Value
  2. CleanCap Reagents
    1. CleanCap Reagents By Value
  3. ARCA (Anti-Reverse Cap Analog)
    1. ARCA (Anti-Reverse Cap Analog) By Value
  4. Others
    1. Others By Value
3. Nucleotides
  1. By Value
  2. Modified Nucleic Acids
    1. Modified Nucleic Acids By Value
    2. N1-methylpseudouridine-triphosphate
      1. N1-methylpseudouridine-triphosphate By Value
    3. 5-Methylcytidine triphosphate (5mCTP)
      1. 5-Methylcytidine triphosphate (5mCTP) By Value
    4. Others
      1. Others By Value
4. Natural Nucleic Acids
  1. By Value
  2. Adenine
    1. Adenine By Value
  3. Guanine
    1. Guanine By Value
  4. Cytosine
    1. Cytosine By Value
  5. Uracil
    1. Uracil By Value
5. Plasmid DNA
  1. By Value
6. Enzymes
  1. By Value
  2. Polymerase
    1. Polymerase By Value
  3. RNase Inhibitor
    1. RNase Inhibitor By Value
  4. DNase
    1. DNase By Value
  5. Others
    1. Others By Value
By Application
1. Introduction
  1. Application By Value
2. Vaccine Production
  1. By Value
3. Therapeutics Production
  1. By Value
4. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Biopharmaceutical & Pharmaceutical Companies
  1. By Value
3. CROs & CMOs
  1. By Value
4. Academic & Research Institutes
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Capping Agents
    1. By Value
    2. CleanCap Reagents
      1. CleanCap Reagents By Value
    3. ARCA (Anti-Reverse Cap Analog)
      1. ARCA (Anti-Reverse Cap Analog) By Value
    4. Others
      1. Others By Value
  3. Nucleotides
    1. By Value
    2. Modified Nucleic Acids
      1. Modified Nucleic Acids By Value
      2. N1-methylpseudouridine-triphosphate
        
        N1-methylpseudouridine-triphosphate By Value
      3. 5-Methylcytidine triphosphate (5mCTP)
        
        5-Methylcytidine triphosphate (5mCTP) By Value
      4. Others
        
        Others By Value
  4. Natural Nucleic Acids
    1. By Value
    2. Adenine
      1. Adenine By Value
    3. Guanine
      1. Guanine By Value
    4. Cytosine
      1. Cytosine By Value
    5. Uracil
      1. Uracil By Value
  5. Plasmid DNA
    1. By Value
  6. Enzymes
    1. By Value
    2. Polymerase
      1. Polymerase By Value
    3. RNase Inhibitor
      1. RNase Inhibitor By Value
    4. DNase
      1. DNase By Value
    5. Others
      1. Others By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Vaccine Production
    1. By Value
  3. Therapeutics Production
    1. By Value
  4. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Biopharmaceutical & Pharmaceutical Companies
    1. By Value
  3. CROs & CMOs
    1. By Value
  4. Academic & Research Institutes
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Capping Agents
  1. By Value
  2. CleanCap Reagents
    1. CleanCap Reagents By Value
  3. ARCA (Anti-Reverse Cap Analog)
    1. ARCA (Anti-Reverse Cap Analog) By Value
  4. Others
    1. Others By Value
3. Nucleotides
  1. By Value
  2. Modified Nucleic Acids
    1. Modified Nucleic Acids By Value
    2. N1-methylpseudouridine-triphosphate
      1. N1-methylpseudouridine-triphosphate By Value
    3. 5-Methylcytidine triphosphate (5mCTP)
      1. 5-Methylcytidine triphosphate (5mCTP) By Value
    4. Others
      1. Others By Value
4. Natural Nucleic Acids
  1. By Value
  2. Adenine
    1. Adenine By Value
  3. Guanine
    1. Guanine By Value
  4. Cytosine
    1. Cytosine By Value
  5. Uracil
    1. Uracil By Value
5. Plasmid DNA
  1. By Value
6. Enzymes
  1. By Value
  2. Polymerase
    1. Polymerase By Value
  3. RNase Inhibitor
    1. RNase Inhibitor By Value
  4. DNase
    1. DNase By Value
  5. Others
    1. Others By Value
By Application
1. Introduction
  1. Application By Value
2. Vaccine Production
  1. By Value
3. Therapeutics Production
  1. By Value
4. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Biopharmaceutical & Pharmaceutical Companies
  1. By Value
3. CROs & CMOs
  1. By Value
4. Academic & Research Institutes
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Capping Agents
    1. By Value
    2. CleanCap Reagents
      1. CleanCap Reagents By Value
    3. ARCA (Anti-Reverse Cap Analog)
      1. ARCA (Anti-Reverse Cap Analog) By Value
    4. Others
      1. Others By Value
  3. Nucleotides
    1. By Value
    2. Modified Nucleic Acids
      1. Modified Nucleic Acids By Value
      2. N1-methylpseudouridine-triphosphate
        
        N1-methylpseudouridine-triphosphate By Value
      3. 5-Methylcytidine triphosphate (5mCTP)
        
        5-Methylcytidine triphosphate (5mCTP) By Value
      4. Others
        
        Others By Value
  4. Natural Nucleic Acids
    1. By Value
    2. Adenine
      1. Adenine By Value
    3. Guanine
      1. Guanine By Value
    4. Cytosine
      1. Cytosine By Value
    5. Uracil
      1. Uracil By Value
  5. Plasmid DNA
    1. By Value
  6. Enzymes
    1. By Value
    2. Polymerase
      1. Polymerase By Value
    3. RNase Inhibitor
      1. RNase Inhibitor By Value
    4. DNase
      1. DNase By Value
    5. Others
      1. Others By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Vaccine Production
    1. By Value
  3. Therapeutics Production
    1. By Value
  4. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Biopharmaceutical & Pharmaceutical Companies
    1. By Value
  3. CROs & CMOs
    1. By Value
  4. Academic & Research Institutes
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Capping Agents
  1. By Value
  2. CleanCap Reagents
    1. CleanCap Reagents By Value
  3. ARCA (Anti-Reverse Cap Analog)
    1. ARCA (Anti-Reverse Cap Analog) By Value
  4. Others
    1. Others By Value
3. Nucleotides
  1. By Value
  2. Modified Nucleic Acids
    1. Modified Nucleic Acids By Value
    2. N1-methylpseudouridine-triphosphate
      1. N1-methylpseudouridine-triphosphate By Value
    3. 5-Methylcytidine triphosphate (5mCTP)
      1. 5-Methylcytidine triphosphate (5mCTP) By Value
    4. Others
      1. Others By Value
4. Natural Nucleic Acids
  1. By Value
  2. Adenine
    1. Adenine By Value
  3. Guanine
    1. Guanine By Value
  4. Cytosine
    1. Cytosine By Value
  5. Uracil
    1. Uracil By Value
5. Plasmid DNA
  1. By Value
6. Enzymes
  1. By Value
  2. Polymerase
    1. Polymerase By Value
  3. RNase Inhibitor
    1. RNase Inhibitor By Value
  4. DNase
    1. DNase By Value
  5. Others
    1. Others By Value
By Application
1. Introduction
  1. Application By Value
2. Vaccine Production
  1. By Value
3. Therapeutics Production
  1. By Value
4. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Biopharmaceutical & Pharmaceutical Companies
  1. By Value
3. CROs & CMOs
  1. By Value
4. Academic & Research Institutes
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Capping Agents
    1. By Value
    2. CleanCap Reagents
      1. CleanCap Reagents By Value
    3. ARCA (Anti-Reverse Cap Analog)
      1. ARCA (Anti-Reverse Cap Analog) By Value
    4. Others
      1. Others By Value
  3. Nucleotides
    1. By Value
    2. Modified Nucleic Acids
      1. Modified Nucleic Acids By Value
      2. N1-methylpseudouridine-triphosphate
        
        N1-methylpseudouridine-triphosphate By Value
      3. 5-Methylcytidine triphosphate (5mCTP)
        
        5-Methylcytidine triphosphate (5mCTP) By Value
      4. Others
        
        Others By Value
  4. Natural Nucleic Acids
    1. By Value
    2. Adenine
      1. Adenine By Value
    3. Guanine
      1. Guanine By Value
    4. Cytosine
      1. Cytosine By Value
    5. Uracil
      1. Uracil By Value
  5. Plasmid DNA
    1. By Value
  6. Enzymes
    1. By Value
    2. Polymerase
      1. Polymerase By Value
    3. RNase Inhibitor
      1. RNase Inhibitor By Value
    4. DNase
      1. DNase By Value
    5. Others
      1. Others By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Vaccine Production
    1. By Value
  3. Therapeutics Production
    1. By Value
  4. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Biopharmaceutical & Pharmaceutical Companies
    1. By Value
  3. CROs & CMOs
    1. By Value
  4. Academic & Research Institutes
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Capping Agents
  1. By Value
  2. CleanCap Reagents
    1. CleanCap Reagents By Value
  3. ARCA (Anti-Reverse Cap Analog)
    1. ARCA (Anti-Reverse Cap Analog) By Value
  4. Others
    1. Others By Value
3. Nucleotides
  1. By Value
  2. Modified Nucleic Acids
    1. Modified Nucleic Acids By Value
    2. N1-methylpseudouridine-triphosphate
      1. N1-methylpseudouridine-triphosphate By Value
    3. 5-Methylcytidine triphosphate (5mCTP)
      1. 5-Methylcytidine triphosphate (5mCTP) By Value
    4. Others
      1. Others By Value
4. Natural Nucleic Acids
  1. By Value
  2. Adenine
    1. Adenine By Value
  3. Guanine
    1. Guanine By Value
  4. Cytosine
    1. Cytosine By Value
  5. Uracil
    1. Uracil By Value
5. Plasmid DNA
  1. By Value
6. Enzymes
  1. By Value
  2. Polymerase
    1. Polymerase By Value
  3. RNase Inhibitor
    1. RNase Inhibitor By Value
  4. DNase
    1. DNase By Value
  5. Others
    1. Others By Value
By Application
1. Introduction
  1. Application By Value
2. Vaccine Production
  1. By Value
3. Therapeutics Production
  1. By Value
4. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Biopharmaceutical & Pharmaceutical Companies
  1. By Value
3. CROs & CMOs
  1. By Value
4. Academic & Research Institutes
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Capping Agents
    1. By Value
    2. CleanCap Reagents
      1. CleanCap Reagents By Value
    3. ARCA (Anti-Reverse Cap Analog)
      1. ARCA (Anti-Reverse Cap Analog) By Value
    4. Others
      1. Others By Value
  3. Nucleotides
    1. By Value
    2. Modified Nucleic Acids
      1. Modified Nucleic Acids By Value
      2. N1-methylpseudouridine-triphosphate
        
        N1-methylpseudouridine-triphosphate By Value
      3. 5-Methylcytidine triphosphate (5mCTP)
        
        5-Methylcytidine triphosphate (5mCTP) By Value
      4. Others
        
        Others By Value
  4. Natural Nucleic Acids
    1. By Value
    2. Adenine
      1. Adenine By Value
    3. Guanine
      1. Guanine By Value
    4. Cytosine
      1. Cytosine By Value
    5. Uracil
      1. Uracil By Value
  5. Plasmid DNA
    1. By Value
  6. Enzymes
    1. By Value
    2. Polymerase
      1. Polymerase By Value
    3. RNase Inhibitor
      1. RNase Inhibitor By Value
    4. DNase
      1. DNase By Value
    5. Others
      1. Others By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Vaccine Production
    1. By Value
  3. Therapeutics Production
    1. By Value
  4. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Biopharmaceutical & Pharmaceutical Companies
    1. By Value
  3. CROs & CMOs
    1. By Value
  4. Academic & Research Institutes
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Capping Agents
  1. By Value
  2. CleanCap Reagents
    1. CleanCap Reagents By Value
  3. ARCA (Anti-Reverse Cap Analog)
    1. ARCA (Anti-Reverse Cap Analog) By Value
  4. Others
    1. Others By Value
3. Nucleotides
  1. By Value
  2. Modified Nucleic Acids
    1. Modified Nucleic Acids By Value
    2. N1-methylpseudouridine-triphosphate
      1. N1-methylpseudouridine-triphosphate By Value
    3. 5-Methylcytidine triphosphate (5mCTP)
      1. 5-Methylcytidine triphosphate (5mCTP) By Value
    4. Others
      1. Others By Value
4. Natural Nucleic Acids
  1. By Value
  2. Adenine
    1. Adenine By Value
  3. Guanine
    1. Guanine By Value
  4. Cytosine
    1. Cytosine By Value
  5. Uracil
    1. Uracil By Value
5. Plasmid DNA
  1. By Value
6. Enzymes
  1. By Value
  2. Polymerase
    1. Polymerase By Value
  3. RNase Inhibitor
    1. RNase Inhibitor By Value
  4. DNase
    1. DNase By Value
  5. Others
    1. Others By Value
By Application
1. Introduction
  1. Application By Value
2. Vaccine Production
  1. By Value
3. Therapeutics Production
  1. By Value
4. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Biopharmaceutical & Pharmaceutical Companies
  1. By Value
3. CROs & CMOs
  1. By Value
4. Academic & Research Institutes
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Capping Agents
    1. By Value
    2. CleanCap Reagents
      1. CleanCap Reagents By Value
    3. ARCA (Anti-Reverse Cap Analog)
      1. ARCA (Anti-Reverse Cap Analog) By Value
    4. Others
      1. Others By Value
  3. Nucleotides
    1. By Value
    2. Modified Nucleic Acids
      1. Modified Nucleic Acids By Value
      2. N1-methylpseudouridine-triphosphate
        
        N1-methylpseudouridine-triphosphate By Value
      3. 5-Methylcytidine triphosphate (5mCTP)
        
        5-Methylcytidine triphosphate (5mCTP) By Value
      4. Others
        
        Others By Value
  4. Natural Nucleic Acids
    1. By Value
    2. Adenine
      1. Adenine By Value
    3. Guanine
      1. Guanine By Value
    4. Cytosine
      1. Cytosine By Value
    5. Uracil
      1. Uracil By Value
  5. Plasmid DNA
    1. By Value
  6. Enzymes
    1. By Value
    2. Polymerase
      1. Polymerase By Value
    3. RNase Inhibitor
      1. RNase Inhibitor By Value
    4. DNase
      1. DNase By Value
    5. Others
      1. Others By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Vaccine Production
    1. By Value
  3. Therapeutics Production
    1. By Value
  4. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Biopharmaceutical & Pharmaceutical Companies
    1. By Value
  3. CROs & CMOs
    1. By Value
  4. Academic & Research Institutes
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

mRNA Synthesis Raw Material Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Thermo Fisher Scientific Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Merck KGaA
Maravai LifeSciences
New England Biolabs
GenScript
Takara Bio Inc.
Glen Research
CordenPharma
Catalent, Inc
Evonik Industries AG
Lonza
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Silantes GmbH
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment